Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTA Lung-202: Pumitamig vs Pembrolizumab in First-line Advanced NSCLC with High PD-L1
jRCT2051260034Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of pumitamig in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Progression-free survival by BICR (RECIST v1.1) and Overall survival. Started Apr 2026; status: recruiting.
02
Drugs
pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051260034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260034.